A Comparative Study of Bone Scan Findings and Serum Levels of Tumor Marker CA15-3 in Patients with Breast Carcinoma

Ghadge, M. S.; Naik, Purva P.; Tiwari, Babita; Hegde, Ruprekha M.; Matale, Tanaji J.

doi:10.1007/s12291-011-0168-5

Cited by 8 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer is the most common form of cancer in women and the second leading cause of death due to malignant disease in females after lung cancer [ 1 , 2 ]. In recent years, the incidence of breast cancer has significantly increased in both Eastern and Western countries.…”

Section: Introductionmentioning

confidence: 99%

“…Components of bodily fluids are ideal biomarkers for disease diagnosis because of their simplicity of detection. For example, the serum has long been considered a rich source of biomarkers, and several serum cancer biomarkers, such as cancer antigen 125 (CA125), carcinoembryonic antigen (CEA), and cancer antigen 15-3 (CA15-3), have been proposed [ 2 , 7 , 8 , 9 ]. However, serum protein biomarkers are often not sufficiently sensitive to be used for screening and early diagnosis because their levels reflect tumor burden [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nipple Discharge of CA15-3, CA125, CEA and TSGF as a New Biomarker Panel for Breast Cancer

Wang

Qin

Zhang

et al. 2014

IJMS

View full text Add to dashboard Cite

Breast cancer is the second leading cause of cancer death in women. Serum biomarkers such as cancer antigen 15-3 (CA15-3), cancer antigen 125 (CA125), and carcinoembryonic antigen (CEA) can be used as diagnostic and prognostic factors and can also provide valuable information during follow-up. However, serum protein biomarkers show limited diagnostic sensitivity and specificity in stand-alone assays because their levels reflect tumor burden. To validate whether biomarkers in nipple discharge may serve as novel biomarkers for breast cancer, we composed a panel of potential cancer biomarkers, including CA15-3, CA125, CEA, and malignant tumor-specific growth factor (TSGF), and evaluated their expression in both serum and nipple discharge in order to explore the expression and significance of estrogen receptor (ER), progestrone receptor (PR), epidermal growth factor receptor type 2 (HER2/neu), CA15-3, CA125, CEA, and TSGF expression for their combined predictive value for breast cancer and in judging the prognosis of breast cancer. Univariate analysis revealed that combined detection of CA15-3, CA125, CEA, and TSGF in nipple discharge served as novel biomarkers for the diagnosis and prognosis of breast cancer, but in the multivariate analyses the adverse effects of the four biomarkers combination in nipple discharge positivity on overall survival were lost. Multivariate analysis revealed that the positivity of the combined detection of the four biomarkers in both nipple discharge and serum was significantly higher than that of other detection methods. Thus, the combined detection of these four biomarkers both in serum and nipple discharge was retained as an independent prognostic variable in breast cancer patients. Our results indicate that CA15-3, CA125, CEA, and TSGF in nipple discharge can serve as novel biomarkers in the diagnosis and prognosis of breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Nipple Discharge of CA15-3, CA125, CEA and TSGF as a New Biomarker Panel for Breast Cancer

Wang

Qin

Zhang

et al. 2014

IJMS

View full text Add to dashboard Cite

show abstract

“…Bone metastasis is very common in breast cancer affecting approximately 70% of patient (1,2). The detection of bone metastasis accurately reflects the prognosis and the early detection in the asymptomatic case may alert the clinician to the possible complications inherit in skeletal destruction (3,4).…”

Section: Introductionmentioning

confidence: 99%

Correlation between Bone Scan Findings and CA 153 in Patients with Carcinoma Breast

Sharmin¹,

Haque

Rahman

et al. 2018

Bangladesh J. Nuclear Med.

View full text Add to dashboard Cite

Objectives: Breast carcinoma is the most life threatening malignant condition in women. This malignant disease commonly metastasizes to bone. Carbohydrate antigen (CA) 15-3 is a circulating human breast cancer associated antigen used as a tumor marker in the screening of breast cancer patients for metastasis. The objective of this study was to compare the levels of CA 15-3 and bone scan findings in patients with breast cancer.Patients and Methods: This cross sectional study was carried out at Institute of Nuclear Medicine and Allied sciences, Mitford, Dhaka, from January 2015 to December 2015. A total of 75 diagnosed breast cancer patients were enrolled in this study. All of them underwent bone scan. The tumor maker CA 15-3 was compared with bone scan findings. Pearson’s correlation coefficient test was done to see the relationship between bone scan and CA 15-3.Results: Mean age of the patients was 47.60 ± 10.53 years (range 25 to 65 years). About half (49%) of the patients belong to the age group 50 years and above. Mean ± SD of CA 15-3 was 84.06 ± 104.60 U/ml (range from 10.12 to 395.30 U/ml). Out of 75 patients, 33 patients showed elevated CA 15-3 level, among them 42% had negative bone scan with mean ± SD CA 15-3 level 60.98 ± 9.95 U/ml (range 40.26-72.17 U/ml), 58% patients had positive bone scan with mean ± SD CA 15-3 level 246.23 ± 81.35U/ml (range 110-395.30 U/ml). CA 15-3 was within normal limit (range 10.20-30.10 U/ml) in 42 patients. Among them 29% patients had negative bone scan and 71% patients had positive bone scan. Pearson’s correlation coefficient test showed positive relationship (p = 0.001, r = 0.343) between CA 15-3 level and bone scan findings.Conclusion: The result of the study showed positive relationship between the bone scan findings and CA 15-3 level of carcinoma breast patients.Bangladesh J. Nuclear Med. 20(1): 24-26, January 2017

show abstract

“…It was found as the first breast cancer‐associated antigen in 1984 7. After decades of experimental research on it, investigators had found that CA15‐3 could be used as diagnostic and prognostic factor and could also provide valuable information during follow‐up 8, 9, 10, 11. Thus, measurement of CA15‐3 is significant for breast cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a newly developed quantitative determination kit for tumor marker CA15‐3 with chemiluminescent assay

Liu³

et al. 2017

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundTumor marker carbohydrate antigen 15‐3 (CA15‐3) is used as a biomarker to aid to diagnose and monitor the prognosis of breast cancer patients. A new quantitative determination kit for CA15‐3 with chemiluminescent assay was developed by Xiamen InnoDx Biotech Co., Ltd, China. Therefore, we conducted the report to evaluate the performance of the kit.MethodsAccording to the “Guiding principles on performance analysis of diagnostic reagents in vitro”, the calibration curve, limit of detection, reportable range, accuracy, precision, anti‐interference capability, cross‐reaction and comparison by measuring EDTA plasma and serum were carried out. In addition, the kit was performed in parallel to electrochemiluminescence immunoassay kit (Roche) to analyze the correlation between the two kits.ResultsRegression equation of calibration curve of the kit was Y=0.7914X+4.1032 (R2=.990). Limit of detection was 0.0347 U/mL. The reportable range was 0.5‐2400 U/mL. Recovery ratio was 100.0%‐104.8%. Coefficient of variations (CVs) of within‐run and between‐run were 4.8%‐7.6% and 5.8%‐7.4% respectively. No remarkable interferences (all Bias% were less than ±10%) were detected when samples contained hemoglobin ≤183.8 μmol/L, bilirubin ≤340 μmol/L, triglyceride ≤18.1 mmol/L, or rheumatoid factor ≤400 U/mL. No cross‐reaction was present in the kit. Moreover, compared with the results from electrochemiluminescence immunoassay kit (Roche) in 345 serum samples, there was a satisfied correlation coefficient of 0.977 (P<.01), and the kit was simultaneously fit for the detection of EDTA plasma and serum samples.ConclusionThe new kit validated satisfactorily, and it can be used for detecting CA15‐3 in clinical practice.

show abstract

A Comparative Study of Bone Scan Findings and Serum Levels of Tumor Marker CA15-3 in Patients with Breast Carcinoma

Cited by 8 publications

References 14 publications

Nipple Discharge of CA15-3, CA125, CEA and TSGF as a New Biomarker Panel for Breast Cancer

Nipple Discharge of CA15-3, CA125, CEA and TSGF as a New Biomarker Panel for Breast Cancer

Correlation between Bone Scan Findings and CA 153 in Patients with Carcinoma Breast

Evaluation of a newly developed quantitative determination kit for tumor marker CA15‐3 with chemiluminescent assay

Contact Info

Product

Resources

About